{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Day J"],"funding":["Medical Research Council","Wellcome Trust"],"pagination":["441"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4289250"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15"],"pubmed_abstract":["<h4>Background</h4>Cryptococcal meningitis (CM) is a severe AIDS-defining illness with 90-day case mortality as high as 70% in sub-Saharan Africa, despite treatment. It is the leading cause of death in HIV patients in Asia and Africa.No major advance has been made in the treatment of CM since the 1970s. The mainstays of induction therapy are amphotericin B and flucytosine, but these are often poorly available where the disease burden is highest. Adjunctive treatments, such as dexamethasone, have had dramatic effects on mortality in other neurologic infections, but are untested in CM. Given the high death rates in patients receiving current optimal treatment, and the lack of new agents on the horizon, adjuvant treatments, which offer the potential to reduce mortality in CM, should be tested"],"journal":["Trials"],"pubmed_title":["CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial."],"pmcid":["PMC4289250"],"funding_grant_id":["G1100684","089276"],"pubmed_authors":["Chau TT","Mayxay M","van Oosterhout JJ","Day N","Cuc NT","Thuy PT","Chau NV","Day J","Phuong L","Rattanavong S","Lalloo DG","Thwaites G","Kamali A","Phetsouvanh R","Ruzagira E","Chan AK","Binh TQ","Newton P","Dance D","Wolbers M","Imran D","Wahyuningsih R","Merson L","Tjahjani N","Chierakul W","Tho LT","Heyderman R","Beardsley J","Gray A","Kibengo F","Hien TT","Van Kinh N","Ganiem AR","Farrar J","Adawiyah R","Wertheim H"],"additional_accession":[]},"is_claimable":false,"name":"CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.","description":"<h4>Background</h4>Cryptococcal meningitis (CM) is a severe AIDS-defining illness with 90-day case mortality as high as 70% in sub-Saharan Africa, despite treatment. It is the leading cause of death in HIV patients in Asia and Africa.No major advance has been made in the treatment of CM since the 1970s. The mainstays of induction therapy are amphotericin B and flucytosine, but these are often poorly available where the disease burden is highest. Adjunctive treatments, such as dexamethasone, have had dramatic effects on mortality in other neurologic infections, but are untested in CM. Given the high death rates in patients receiving current optimal treatment, and the lack of new agents on the horizon, adjuvant treatments, which offer the potential to reduce mortality in CM, should be tested","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Nov","modification":"2026-07-15T22:23:19.282Z","creation":"2026-07-09T10:19:09.426Z"},"accession":"S-EPMC4289250","cross_references":{"pubmed":["25391338"],"doi":["10.1186/1745-6215-15-441"]}}